Search research articles
Contact Us
Filters
Showing results (251-260 of 440) with videos related to
Page
of 44
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
August 23, 2015
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma
Jonathon B Cohen, Silvana Bucur, Elliott F Winton, et al.
Blood Advances
|
February 6, 2025
Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma
Sayalee V Potdar, Shivani Kapadia, Maryam I Azeem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2010
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study
Sagar Lonial, Jonathan Kaufman, Mourad Tighiouart, et al.
Cancer
|
November 6, 2018
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
Ajai Chari, Sagar Lonial, Tomer M Mark, et al.
Advances in Therapy
|
February 21, 2020
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses
Xu Steven Xu, Philippe Moreau, Saad Z Usmani, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 8, 2025
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes
Cindy Varga, Myra Robinson, Vikas Gupta, et al.
Leukemia & Lymphoma
|
September 6, 2011
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma
Disni Muringampurath-John, Christopher R Flowers, Michael Toscano, et al.
Cancer Chemotherapy and Pharmacology
|
March 23, 2010
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma
Donna E Reece, Dan Sullivan, Sagar Lonial, et al.
Blood
|
September 25, 2024
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis
Rahul Banerjee, Rachael Sexton, Andrew J Cowan, et al.
Blood
|
June 23, 2017
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari, Attaya Suvannasankha, Joseph W Fay, et al.
Page
of 44
Search research articles
Search
Showing results (251-260 of 440) with videos related to
Sort By:
Page
of 44
Clinical Lymphoma, Myeloma & Leukemia
|
August 23, 2015
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma
Jonathon B Cohen, Silvana Bucur, Elliott F Winton, et al.
Blood Advances
|
February 6, 2025
Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma
Sayalee V Potdar, Shivani Kapadia, Maryam I Azeem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2010
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study
Sagar Lonial, Jonathan Kaufman, Mourad Tighiouart, et al.
Cancer
|
November 6, 2018
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
Ajai Chari, Sagar Lonial, Tomer M Mark, et al.
Advances in Therapy
|
February 21, 2020
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses
Xu Steven Xu, Philippe Moreau, Saad Z Usmani, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 8, 2025
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes
Cindy Varga, Myra Robinson, Vikas Gupta, et al.
Leukemia & Lymphoma
|
September 6, 2011
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma
Disni Muringampurath-John, Christopher R Flowers, Michael Toscano, et al.
Cancer Chemotherapy and Pharmacology
|
March 23, 2010
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma
Donna E Reece, Dan Sullivan, Sagar Lonial, et al.
Blood
|
September 25, 2024
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis
Rahul Banerjee, Rachael Sexton, Andrew J Cowan, et al.
Blood
|
June 23, 2017
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari, Attaya Suvannasankha, Joseph W Fay, et al.
Page
of 44